NB

Neurocrine Biosciences

Every trial this sponsor leads in the registry, and everything it has published.

81All trials
Recruiting13
Recruited2
By invitation1
Completed53
Stopped12

16 active · 20% of this sponsor’s registry footprint

Psychiatry & Addiction12 trials
Renal & Urology2 trials
Neurology1 trial

Not shown above: 1 trial whose condition matched no therapy area.

Trials by phase

Phase 121
Phase 234
Phase 322
Phase 44

Pipeline by phase · 6 drugs in active development

Phase 3 · 3 drugs

Direclidine (NBI-1117568)5 trials · 5 recruitingest. Oct 2027
Osavampator (NBI-1065845)5 trials · 5 recruitingest. Jul 2027
Crinecerfont2 trials

Phase 2 · 2 drugs

NBI-10658901 trial · 1 recruitingest. Feb 2027
NBI-11175701 trial · 1 recruitingest. Aug 2027

Phase 4 · 1 drug

Valbenazine2 trials · 1 recruitingest. Jan 2027

Active trials only, code names and brands merged. 53 completed trials are in the counts above but their drugs are not folded into this pipeline.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon